DOCSLIB.ORG

Role of MRP1 in Multidrug Resistance in Acute Myeloid Leukemia O Legrand, R Zittoun and J-P Marie

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of MRP1 in Multidrug Resistance in Acute Myeloid Leukemia O Legrand, R Zittoun and J-P Marie Leukemia (1999) 13, 578–584 1999 Stockton Press All rights reserved 0887-6924/99 $12.00 http://www.stockton-press.co.uk/leu Role of MRP1 in multidrug resistance in acute myeloid leukemia O Legrand, R Zittoun and J-P Marie EA1529, Universite´ Paris 6, Formation de Recherche Claude Bernard, and Service d’He´matologie, Hoˆpital Hoˆtel-Dieu, AP-HP, Paris, France The best characterized resistance mechanism in adult acute drugs among which are doxorubicin, daunorubicin, idarub- myeloid leukemia (AML) is the one mediated by the MDR1 gene icin, mitoxantrone and etoposide.13,14 At least in transfectants, which has been shown to be associated with poor outcome. However, alternative proteins such as the more recently recog- MRP1 is able to act as an energy-dependent drug pump, nized multidrug-associated protein (MRP1), may also contrib- mainly localized in the plasma membrane, that extrudes drugs ute to the resistance to anthracyclines and etoposide in AML. from the cell against a concentration gradient.14–17 It has been Recently, the role of this protein was discussed and was shown that MRP1 is identical to a GSH-S conjugate carrier unclear in AML. However, recent data concerning the func- described in many cells, because the endogenous leukotriene tionality and the modulation of the activity of MRP1 may eluci- C4 and other GSH-S conjugates are transported by MRP1.18–22 date its role in comparison with other mechanisms of resist- ance. In this paper, we will review these recent data concerning Recently, it was shown that ATP-dependent uptake of the the role of MRP1 in adult AML. unmodified drug vincristine by membrane vesicles derived Keywords: MDR; MRP1; acute myeloid leukemia; functional test; from MRP1 transfected HeLa cells is dependent on the pres- prognostic factor ence of GSH. It is possible that GSH interacts directly with MRP1 and that this interaction is necessary for transport. In addition, GSH depletion by buthionine sulphoximine (BSO) Introduction increases the accumulation of DNR and Rhodamine 123 (Rh123) in several MRP1-positive cell lines.21 Therefore, The use of the first cytostatic agents produced a dramatic MRP1 is a multiple organic anion transporter, it transports cer- improvement in the management of acute myeloid leukemia tain glutathione conjugates and may be partly dependent on (AML), but drug resistance eventually arose during chemo- intracellular glutathione levels for the transport of anthracy- therapy. Among different mechanisms of resistance, the clines. Marbeuf-Gueye et al23 studied the transport kinetics of appearance of the multidrug resistance (MDR) phenotype is a series of anthracyclines in tumor cell lines that overexpress the most frequently observed in many cancer cell lines MRP1 and Pgp. They showed that the transport kinetics of (including leukemia). The best characterized resistance mech- anthracyclines by MRP1 and Pgp are very similar except for anism is the one mediated by the MDR1 gene which has been OH-DOX and OH-DNR which had a lower VMax (maximal shown to be associated with poor outcome.1 However, alter- efflux rate) in the case of MRP1-mediated transport suggesting native proteins such as the multidrug-associated protein a role for the amino group in the interaction with glutathione. (MRP1), may also contribute to the resistance to anthracy- On the other hand, Lorico et al24 compared the sensitivity clines and etoposide in AML.2,3 The role of MRP1 is still being to chemotherapeutic drugs and toxins of wild-type W9.5 discussed and is unclear in AML.4–11 In this paper, we will embryonic stem cells and of single and double MRP1 gene review recent data concerning the role of MRP1 in adult AML. knockout cells derived there from. MRP1 expression was tot- ally abrogated in the double knockout cell line and partially abrogated in the single knockout cell line. RT-PCR analyses Structure and function of MRP1 demonstrated that MDR1 gene was not expressed. The cyto- toxic activities of etoposide, teniposide, vincristine, doxorub- The MRP1 gene is located on chromosome 16p13.1. MRP1, icin, daunorubicin and sodium arsenite were significantly like Pgp belongs to the ATP binding cassette (ABC) super- greater in double knockout cells than in parenteral wild-type family of membrane transport protein. It is a glycosylated ES cells. These findings indicate that baseline MRP1 transmembrane protein of 190 kDa.2 Bakos et al’s12 experi- expression has the capacity to exert a protective role against ment and the alignment of the MRP1 sequence with the the toxicity of multiple chemotherapeutic agents and natural human cystic fibrosis transmembrane conductance (CFTR) toxins. In the same way, deletion of the MRP1 gene was found suggest that human MRP1 contains a tandem repeat of six previously in five of 13 AML patients with inv(16) and was transmembrane helices, each followed by a nucleotide bind- associated with longer overall survival and disease-free sur- ing domain and that the C-terminal membrane-bound region vival.25 This aberration was suggested as being the reason for is glycosylated. The N-terminal region of MRP1 contains an the better prognosis of patients with inv(16) in this small series additional membrane-bound, glycosylated area with four or of patients. However, lack of MDR1 gene expression might five transmembrane helices, which seems to be a character- be an alternative explanation for the good prognosis of these istic feature of MRP-like ATP-binding cassette transporters. patients with inv(16).25 Transfection experiments with different eukaryotic Zaman et al26 have shown that in the MRP-overexpressing expression vectors containing full-length complementary cell line GLC4/ADR the MRP1 gene copy number is increased DNAs of the MRP1 gene have shown that MRP1 can confer, about 25-fold, as compared to the parental cell line. However, just like Pgp, resistance to a broad range of natural product no AML patients analyzed by Burger et al,27,28 including those who had high MRP mRNA expression showed evidence for MRP1 gene amplification. Therefore, they concluded that the increase in MRP1 expression in AML patients was not associa- Correspondence: O Legrand, Hoˆpital Hoˆtel Dieu, 1 place du parvis Notre Dame, Service d’he´matologie, 75 181 Paris Cedex 04, France; ted with amplification of the cognate gene. 29 Fax: 33 1 42 34 82 54 Ma et al demonstrated that MRP1 is highly phosphoryl- Received 29 September 1998; accepted 9 December 1998 ated and that phosphate groups are metabolically active and MRP1 in AML O Legrand et al 579 undergo cycles of phosphorylation and dephosphorylation in bone marrow cells, while we have shown that MRP1 activity the cell. Serine is the single amino acid phosphorylated in was higher in CD34− than in CD34+ leukemia cells.11 MRP1. The effect of H-7 and staurosporine (two protein kinase Several studies on MRP1 expression in AML have been inhibitors) can reduce the phosphorylation of this protein. It reported. The incidence of MRP1 gene overexpression in AML has also been found that, in the presence of these agents, there patients was obtained by RNA or protein techniques. Messen- is a major increase in drug accumulation and concomitant ger RNA was quantified using either RT-PCR or by RNase pro- inhibition in drug efflux of resistant cells. Therefore, certain tection assay. Protein was recently detected by immunocyto- phosphate groups of protein MRP1 play an important role in chemistry, Western blot and flow cytometry with monoclonal modulating drug accumulation in resistant cells. antibodies (MRPm6, MRPr1, QRL-1 and QRL-3).4,6–8,10,11,28,39–43 The DNA containing promoter activity has been sequenced All these antibodies recognize an internal epitope of in its entirety and found to contain multiple putative regulat- MRP1.16,17 Few comparative analyses between these tech- ory sites. Studies using a number of different deletion mutants niques have been published. Filipits et al44 showed that there suggest that the major promoter activity of MRP1 resides in a was a fair correlation between results obtained with QCRL- highly GC-rich region of 914 nucleotides (nucleosides −91 to 1/QCRL-3 and those obtained with MRPr1 by immunocytoch- +103). Promoter activity contained within this sequence, how- emistry for AML patients. In other studies we have demon- ever, is modulated by both positive and negative regulatory strated that three techniques (RT-PCR, in situ hybridation and elements.30 The functional analysis of the nucleotide binding protein detection by flow cytometry) gave similar results in domains of MRP1 identify several mutations that are critical normal hematopoietic cells and in fresh leukemic cells.11,39 for MRP-mediated multidrug resistance.31 Recently, besides MRP1 at least four other homologues of Analyses of the subcellular distribution of MRP1 in cell lines these proteins (these new genes were called MRP2 to MRP5) revealed that approximatively 80% of MRP1 in the SW-1573 have been identified.45 However, MRP3 and MRP5 were only and HeLa transfectants were associated with plasma mem- overexpressed in a few cell lines, and the RNA levels did not brane, while the comparable localization in the drug-selected seem to correlate with resistance to either doxorubicin or cis- H69AR cells contained only approximatively 50% of the pro- platin. MRP4 was not overexpressed in any of the cell lines tein. The remaining MRP1 was codistributed in endocytotic which were analyzed. MRP2 (or cMOAT) was substantially vesicles. The relatively high proportion of MRP1 associated overexpressed in several cell lines, and MRP2 RNA levels cor- with these fractions in H69AR cells may contribute to the lack relate with cisplatin but not doxorubicin resistance in a subset of an observable accumulation defect in these cells when of resistant cell lines. Sequence analysis revealed that the pro- compared with the transfectants.2 In AML cells MRP1 staining tein segment used to generate the MRPm6 antibody was (by immunocytochemistery) was primarily cytoplasmic.32 derived from the most homologous portion located in the C- Several publications have shown that the resistance of cell terminal part of MRP1.
Load more

Recommended publications
  • Cysteinyl Leukotriene Receptor 1/2 Antagonists Nonselectively Modulate Organic Anion Transport by Multidrug Resistance Proteins (MRP1-4) S
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2016/04/11/dmd.116.069468.DC1 1521-009X/44/6/857–866$25.00 http://dx.doi.org/10.1124/dmd.116.069468 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:857–866, June 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Cysteinyl Leukotriene Receptor 1/2 Antagonists Nonselectively Modulate Organic Anion Transport by Multidrug Resistance Proteins (MRP1-4) s Mark A. Csandl, Gwenaëlle Conseil, and Susan P. C. Cole Departments of Biomedical and Molecular Sciences (M.A.C., S.P.C.C.), and Pathology and Molecular Medicine (G.C., S.P.C.C.), Division of Cancer Biology and Genetics, Queen’s University Cancer Research Institute, Kingston, ON, Canada Received January 13, 2016; accepted April 7, 2016 ABSTRACT Active efflux of both drugs and organic anion metabolites is class of antagonists showed any MRP selectivity. For E217bG Downloaded from mediated by the multidrug resistance proteins (MRPs). MRP1 uptake, LTM IC50s ranged from 1.2 to 26.9 mMandweremost (ABCC1), MRP2 (ABCC2), MRP3 (ABCC3), and MRP4 (ABCC4) have comparable for MRP1 and MRP4. The LTM rank order inhibitory partially overlapping substrate specificities and all transport 17b- potencies for E217bGversusLTC4 uptake by MRP1, and E217bG estradiol 17-(b-D-glucuronide) (E217bG). The cysteinyl leukotriene versus PGE2 uptake by MRP4, were also similar. Three of four receptor 1 (CysLT1R) antagonist MK-571 inhibits all four MRP CysLT1R-selective LTMs also stimulated MRP2 (but not MRP3) homologs, but little is known about the modulatory effects of newer transport and thus exerted a concentration-dependent biphasic leukotriene modifiers (LTMs).
    [Show full text]
  • The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus Lee A
    The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus Lee A. Dawson, Ph.D., Huy Q. Nguyen, B.S., and Ping Li, B.S. Preclinical evidence has suggested a possible role for the 5-HT6 increases in extracellular glutamate levels in both frontal receptor in the treatment of cognitive dysfunction. However, cortex and dorsal hippocampus, respectively. These effects were currently there is little neurochemical evidence suggesting the completely attenuated by infusion of tetrodotoxin but mechanism(s) which may be involved. Using the selective unaffected by the muscarinic antagonist, atropine. Here we 5-HT6 antagonist SB-271046 and in vivo microdialysis, we demonstrate for the first time the selective enhancement of have evaluated the effects of this compound on the modulation excitatory neurotransmission by SB-271046 in those brain of basal neurotransmitter release within multiple brain regions regions implicated in cognitive and memory function, and of the freely moving rat. SB-271046 produced no change in provide mechanistic evidence in support of a possible basal levels of dopamine (DA), norepinephrine (NE) or 5-HT therapeutic role for 5-HT6 receptor antagonists in the in the striatum, frontal cortex, dorsal hippocampus or nucleus treatment of cognitive and memory dysfunction. accumbens. Similarly, this compound had no effect on [Neuropsychopharmacology 25:662–668, 2001] excitatory neurotransmission in the striatum or nucleus © 2001 American College of Neuropsychopharmacology. accumbens. Conversely, SB-271046 produced 3- and 2-fold Published by Elsevier Science Inc. KEY WORDS: 5-HT6 receptor; SB-271046; Microdialysis; sma et al. 1993; Ruat et al.
    [Show full text]
  • Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary
    H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome .
    [Show full text]
  • Binding Mode Exploration of B1 Receptor Antagonists' by the Use of Molecular Dynamics and Docking Simulation—How Different T
    International Journal of Molecular Sciences Article Binding Mode Exploration of B1 Receptor Antagonists’ by the Use of Molecular Dynamics and Docking Simulation—How Different Target Engagement Can Determine Different Biological Effects Marica Gemei 1,*, Carmine Talarico 1 , Laura Brandolini 1, Candida Manelfi 1, Lorena Za 2, Silvia Bovolenta 2, Chiara Liberati 2, Luigi Del Vecchio 3, Roberto Russo 4 , Carmen Cerchia 4, Marcello Allegretti 1 and Andrea Rosario Beccari 1 1 Dompé Farmaceutici SpA, via Campo di Pile, 67100 L’Aquila, Italy; [email protected] (C.T.); [email protected] (L.B.); candida.manelfi@dompe.com (C.M.); [email protected] (M.A.); [email protected] (A.R.B.) 2 Axxam, Via Meucci 3, Bresso, 20091 Milano, Italy; [email protected] (L.Z.); [email protected] (S.B.); [email protected] (C.L.) 3 Ceinge Biotecnologie Avanzate, via G. Salvatore 486, 80145 Napoli, Italy; [email protected] 4 Department of Pharmacy, University of Naples “Federico II”, via D. Montesano, 49, 80131 Napoli, Italy; [email protected] (R.R.); [email protected] (C.C.) * Correspondence: [email protected]; Tel.: +34-06-465916 Received: 26 August 2020; Accepted: 12 October 2020; Published: 16 October 2020 Abstract: The kinin B1 receptor plays a critical role in the chronic phase of pain and inflammation. The development of B1 antagonists peaked in recent years but almost all promising molecules failed in clinical trials. Little is known about these molecules’ mechanisms of action and additional information will be necessary to exploit the potential of the B1 receptor.
    [Show full text]
  • The Selective Serotonin2a Receptor Antagonist, MDL100,907, Elicits A
    BRIEF REPORT The Selective Serotonin2A Receptor Antagonist, MDL100,907, Elicits a Specific Interoceptive Cue in Rats Anne Dekeyne, Ph.D., Loretta Iob, B.Sc., Patrick Hautefaye, Ph.D., and Mark J. Millan, Ph.D. Employing a two-lever, food-reinforced, Fixed Ratio 10 5-HT2B/2C antagonist, SB206,553 (0.16 and 2.5 mg/kg) and drug discrimination procedure, rats were trained to the selective 5-HT2C antagonists, SB242,084 (2.5 and recognize the highly-selective serotonin (5-HT)2A receptor 10.0 mg/kg,) and RS102221 (2.5 and 10.0 mg/kg), did not antagonist, MDL100,907 (0.16 mg/kg, i.p.). They attained significantly generalize. In conclusion, selective blockade of Ϯ Ϯ criterion after a mean S.E.M. of 70 11 sessions. 5-HT2A receptors by MDL100,907 elicits a discriminative MDL100,907 fully generalized with an Effective Dose stimulus in rats which appears to be specifically mediated (ED)50 of 0.005 mg/kg, s.c.. A further selective 5-HT2A via 5-HT2A as compared with 5-HT2B and 5-HT2C receptors. antagonist, SR46349, similarly generalized with an ED50 of [Neuropsychopharmacology 26:552–556, 2002] 0.04 mg/kg, s.c. In distinction, the selective 5-HT2B © 2002 American College of Neuropsychopharmacology antagonist, SB204,741 (0.63 and 10.0 mg/kg), the Published by Elsevier Science Inc. KEY WORDS: Drug discrimination; Interoceptive; 5-HT2A stimulus (DS) properties of several 5-HT2 agonists and receptors hallucinogens, such as mescaline (Appel and Callahan 1989), lysergic acid diethylamide (LSD) (Fiorella et al. Drug discrimination procedures have been extensively 1995) and quipazine (Friedman et al.
    [Show full text]
  • Pharmacology/Therapeutics II Block I Lectures – 2013‐14
    Pharmacology/Therapeutics II Block I Lectures – 2013‐14 54. H2 Blocker, PPls – Patel 55. Principles of Clinical Toxicology – Kennedy 56. Anti‐Parasitic Agents – Johnson (To be posted later) 57. Palliation of Constipation & Nausea/vomiting – Kristopaitis (Lecture in Room 190) Tarun B. Patel, Ph.D Date: January 9, 2013: 10:30 a.m. Reading Assignment: Katzung, Basic and Clinical Pharmacology, 11th Edition, pp. 1067-1077. KEY CONCEPTS AND LEARNING OBJECTIVES Histamine via its different receptors produces a number of physiological and pathological actions. Therefore, anti-histaminergic drugs may be used to treat different conditions. 1. To know the physiological functions of histamine. 2. To understand which histamine receptors mediate the different effects of histamine in stomach ulcers. 3. To know what stimuli cause the release of histamine and acid in stomach. 4. To know the types of histamine H2 receptor antagonists that are available clinically. 5. To know the clinical uses of H2 receptor antagonists. 6. To know the drug interactions associated with the use of H2 receptor antagonists. 7. To understand the mechanism of action of PPIs 8. To know the adverse effects and drugs interactions with PPIs 9. To know the role of H. pylori in gastric ulceration 10. To know the drugs used to treat H. pylori infection Drug List: See Summary Table Provided at end of handout. Page 1 Tarun B. Patel, Ph.D Histamine H2 receptor antagonists and PPIs in the treatment of GI Ulcers: The following section covers medicines used to treat ulcer. These medicines include H2 receptor antagonists, proton pump inhibitors, mucosal protective agents and antibiotics (for treatment of H.
    [Show full text]
  • Drug Action-Receptor Theory
    Drug action-Receptor Theory Molecules (eg, drugs, hormones, neurotransmitters) that bind to a receptor are called ligands. The binding can be specific and reversible. A ligand may activate or inactivate a receptor; activation may increase or decrease a particular cell function. Each ligand may interact with multiple receptor subtypes. Few if any drugs are absolutely specific for one receptor or subtype, but most have relative selectivity. Selectivity is the degree to which a drug acts on a given site relative to other sites; selectivity relates largely to physicochemical binding of the drug to cellular receptors. A drug’s ability to affect a given receptor is related to the drug’s affinity (probability of the drug occupying a receptor at any given instant) and intrinsic efficacy (intrinsic activity—degree to which a ligand activates receptors and leads to cellular response). A drug’s affinity and activity are determined by its chemical structure. The pharmacologic effect is also determined by the duration of time that the drug-receptor complex persists (residence time). The lifetime of the drug-receptor complex is affected by dynamic processes (conformation changes) that control the rate of drug association and dissociation from the target. A longer residence time explains a prolonged pharmacologic effect. Drugs with long residence times include finasteride and darunavir. A longer residence time can be a potential disadvantage when it prolongs a drug's toxicity. For some receptors, transient drug occupancy produces the desired pharmacologic effect, whereas prolonged occupancy causes toxicity. Ability to bind to a receptor is influenced by external factors as well as by intracellular regulatory mechanisms.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • Pharmacokinetics and Pharmacology of Drugs Used in Children
    Drug and Fluid Th erapy SECTION II Pharmacokinetics and Pharmacology of Drugs Used CHAPTER 6 in Children Charles J. Coté, Jerrold Lerman, Robert M. Ward, Ralph A. Lugo, and Nishan Goudsouzian Drug Distribution Propofol Protein Binding Ketamine Body Composition Etomidate Metabolism and Excretion Muscle Relaxants Hepatic Blood Flow Succinylcholine Renal Excretion Intermediate-Acting Nondepolarizing Relaxants Pharmacokinetic Principles and Calculations Atracurium First-Order Kinetics Cisatracurium Half-Life Vecuronium First-Order Single-Compartment Kinetics Rocuronium First-Order Multiple-Compartment Kinetics Clinical Implications When Using Short- and Zero-Order Kinetics Intermediate-Acting Relaxants Apparent Volume of Distribution Long-Acting Nondepolarizing Relaxants Repetitive Dosing and Drug Accumulation Pancuronium Steady State Antagonism of Muscle Relaxants Loading Dose General Principles Central Nervous System Effects Suggamadex The Drug Approval Process, the Package Insert, and Relaxants in Special Situations Drug Labeling Opioids Inhalation Anesthetic Agents Morphine Physicochemical Properties Meperidine Pharmacokinetics of Inhaled Anesthetics Hydromorphone Pharmacodynamics of Inhaled Anesthetics Oxycodone Clinical Effects Methadone Nitrous Oxide Fentanyl Environmental Impact Alfentanil Oxygen Sufentanil Intravenous Anesthetic Agents Remifentanil Barbiturates Butorphanol and Nalbuphine 89 A Practice of Anesthesia for Infants and Children Codeine Antiemetics Tramadol Metoclopramide Nonsteroidal Anti-infl ammatory Agents 5-Hydroxytryptamine
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Histamine and Antihistamines Sites of Action Conditions Which Cause Release Aron H
    Learning Objectives I Histamine Pharmacological effects Histamine and Antihistamines Sites of action Conditions which cause release Aron H. Lichtman, Ph.D. Diagnostic uses Associate Professor II Antihistamines acting at the H1 and H2 receptor Pharmacology and Toxicology Pharmacological effects Mechanisms of action Therapeutic uses Side effects and drug interactions Be familiar with the existence of the H3 receptor III Be able to describe the main mechanism of action of cromolyn sodium and its clinical uses Histamine Pharmacology First autacoid to be discovered. (Greek: autos=self; Histamine Formation akos=cure) Synthesized in 1907 Synthesized in mammalian tissues by Demonstrated to be a natural constituent of decarboxylation of the amino acid l-histidine mammalian tissues (1927) Involved in inflammatory and anaphylactic reactions. Local application causes swelling redness, and edema, mimicking a mild inflammatory reaction. Large systemic doses leads to profound vascular changes similar to those seen after shock or anaphylactic origin Histamine Stored in complex with: Heparin Chondroitin Sulfate Eosinophilic Chemotactic Factor Neutrophilic Chemotactic Factor Proteases 1 Conditions That Release Histamine 1. Tissue injury: Any physical or chemical agent that injures tissue, skin or mucosa are particularly sensitive to injury and will cause the immediate release of histamine from mast cells. 2. Allergic reactions: exposure of an antigen to a previously sensitized (exposed) subject can immediately trigger allergic reactions. If sensitized by IgE antibodies attached to their surface membranes will degranulate when exposed to the appropriate antigen and release histamine, ATP and other mediators. 3. Drugs and other foreign compounds: morphine, dextran, antimalarial drugs, dyes, antibiotic bases, alkaloids, amides, quaternary ammonium compounds, enzymes (phospholipase C).
    [Show full text]
  • Mediated Multidrug Resistance (MDR) in Cancer
    A Thesis Entitled: Differential Effects of Dopamine D3 Receptor Antagonists in Modulating ABCG2 - Mediated Multidrug Resistance (MDR) in Cancer by Noor A. Hussein Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science in Pharmaceutical Sciences Degree in Pharmacology and Toxicology _________________________________________ Dr. Amit K. Tiwari, Committee Chair _________________________________________ Dr. Frank Hall , Committee Member _________________________________________ Dr. Zahoor Shah, Committee Member _________________________________________ Dr. Caren Steinmiller, Committee Member _________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo May 2017 Copyright 2017, Noor A. Hussein This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Differential Effects of Dopamine D3 Receptor Antagonists in Modulating ABCG2 - Mediated Multidrug Resistance (MDR) by Noor A. Hussein Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science in Pharmaceutical Sciences Degree in Pharmacology and Toxicology The University of Toledo May 2017 The G2 subfamily of the ATP-binding cassette transporters (ABCG2), also known as the breast cancer resistance protein (BRCP), is an efflux transporter that plays an important role in protecting the cells against endogenous and exogenous toxic substances. The ABCG2 transporters are also highly expressed in the blood brain barrier (BBB), providing protection against specific toxic compounds. Unfortunately, their overexpression in cancer cells results in the development of multi-drug resistance (MDR), and thus, chemotherapy failure. Dopamine3 receptor (D3R) antagonists were shown to have excellent anti-addiction properties in preclinical animal models but produced limited clinical success with the lead molecule.
    [Show full text]